The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 4,004 | 42,030 | SH | SOLE | 42,030 | 0 | 0 | ||
| Blueprint Medicines Corporation | COM | 09627Y109 | 19,469 | 249,598 | SH | SOLE | 249,598 | 0 | 0 | ||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 5,584 | 1,599,958 | SH | SOLE | 1,599,958 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 16,032 | 998,278 | SH | SOLE | 998,278 | 0 | 0 | ||
| FibroGen, Inc. | COM | 31572Q808 | 1,621 | 40,000 | SH | SOLE | 40,000 | 0 | 0 | ||
| Myokardia, Inc. | COM | 62857M105 | 38,586 | 399,360 | SH | SOLE | 399,360 | 0 | 0 | ||
| Natera, Inc. | COM | 632307104 | 10,409 | 208,768 | SH | SOLE | 208,768 | 0 | 0 | ||
| Oric Pharmaceuticals, Inc. | COM | 68622P109 | 16,760 | 496,893 | SH | SOLE | 496,893 | 0 | 0 | ||